1,4-dihydropyridine has been researched along with Osteogenic Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, U; Duncan, R; Harter, L; Hruska, K; Kizer, N | 1 |
| Caffrey, JM; Farach-Carson, MC | 1 |
2 other study(ies) available for 1,4-dihydropyridine and Osteogenic Sarcoma
| Article | Year |
|---|---|
Volume regulatory decrease in UMR-106.01 cells is mediated by specific alpha1 subunits of L-type calcium channels.
Topics: Animals; Bone Neoplasms; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Cell Size; Dihydropyridines; Hypotonic Solutions; Nifedipine; Oligonucleotides, Antisense; Osmolar Concentration; Osteoblasts; Osteosarcoma; Patch-Clamp Techniques; Protein Isoforms; Rats; Tumor Cells, Cultured | 1999 |
Vitamin D3 metabolites modulate dihydropyridine-sensitive calcium currents in clonal rat osteosarcoma cells.
Topics: 24,25-Dihydroxyvitamin D 3; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Barium; Calcifediol; Calcitriol; Calcium; Calcium Channels; Cell Line; Dihydropyridines; Kinetics; Membrane Potentials; Osteosarcoma; Rats; Tumor Cells, Cultured | 1989 |